NASDAQ:BIOC - Biocept Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.02 -0.02 (-1.92 %) (As of 03/25/2019 03:49 PM ET)Previous Close$1.04Today's Range$1.00 - $1.0352-Week Range$0.66 - $12.15Volume24,070 shsAverage Volume2.40 million shsMarket Capitalization$2.32 millionP/E Ratio-0.04Dividend YieldN/ABeta2.9 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California. Receive BIOC News and Ratings via Email Sign-up to receive the latest news and ratings for BIOC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOC Previous Symbol CUSIPN/A CIK1044378 Webwww.biocept.com Phone858-320-8200Debt Debt-to-Equity Ratio0.11 Current Ratio2.63 Quick Ratio2.50Price-To-Earnings Trailing P/E Ratio-0.04 Forward P/E Ratio-0.11 P/E GrowthN/A Sales & Book Value Annual Sales$5.07 million Price / Sales0.46 Cash FlowN/A Price / Cash FlowN/A Book Value$0.61 per share Price / Book1.67Profitability EPS (Most Recent Fiscal Year)($23.72) Net Income$-21,610,000.00 Net Margins-715.42% Return on Equity-456.20% Return on Assets-215.56%Miscellaneous EmployeesN/A Outstanding Shares2,270,000Market Cap$2.32 million Next Earnings Date3/28/2019 (Confirmed) OptionableOptionable Biocept (NASDAQ:BIOC) Frequently Asked Questions What is Biocept's stock symbol? Biocept trades on the NASDAQ under the ticker symbol "BIOC." How were Biocept's earnings last quarter? Biocept Inc (NASDAQ:BIOC) released its earnings results on Tuesday, August, 14th. The medical research company reported ($2.70) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($3.30) by $0.60. The medical research company had revenue of $0.82 million for the quarter, compared to the consensus estimate of $1.09 million. Biocept had a negative return on equity of 456.20% and a negative net margin of 715.42%. View Biocept's Earnings History. When is Biocept's next earnings date? Biocept is scheduled to release their next quarterly earnings announcement on Thursday, March 28th 2019. View Earnings Estimates for Biocept. What price target have analysts set for BIOC? 2 Wall Street analysts have issued 1 year price objectives for Biocept's stock. Their predictions range from $1.00 to $1.00. On average, they anticipate Biocept's share price to reach $1.00 in the next year. This suggests that the stock has a possible downside of 2.0%. View Analyst Price Targets for Biocept. What is the consensus analysts' recommendation for Biocept? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biocept. Has Biocept been receiving favorable news coverage? News articles about BIOC stock have been trending positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biocept earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the company's share price in the near future. Are investors shorting Biocept? Biocept saw a decline in short interest during the month of February. As of February 15th, there was short interest totalling 466,391 shares, a decline of 76.2% from the January 31st total of 1,957,896 shares. Based on an average trading volume of 1,888,253 shares, the short-interest ratio is currently 0.2 days. Approximately 11.3% of the company's shares are short sold. View Biocept's Current Options Chain. Who are some of Biocept's key competitors? Some companies that are related to Biocept include CBA Florida (CBAI), OpGen (OPGN), Cancer Genetics (CGIX), Aeon Global Health (AGHC), Avant Diagnostics (AVDX) and Foundation Medicine (FMI). What other stocks do shareholders of Biocept own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include Synergy Pharmaceuticals (SGYP), TrovaGene (TROV), Cytori Therapeutics (CYTX), SCYNEXIS (SCYX), AVEO Pharmaceuticals (AVEO), Exelixis (EXEL), Vascular Biogenics (VBLT), Neovasc (NVCN), Progenics Pharmaceuticals (PGNX) and Biopharmx (BPMX). Who are Biocept's key executives? Biocept's management team includes the folowing people: Mr. Michael W. Nall, CEO, Pres & Director (Age 56)Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations & Corp. Sec. (Age 61)Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer and Member of Scientific Advisory Board (Age 72)Dr. Soon Kap Hahn Ph.D., FounderMr. Pavel Tsinberg, Director of Technology Devel. Who are Biocept's major shareholders? Biocept's stock is owned by many different of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (4.86%) and Dimensional Fund Advisors LP (4.86%). View Institutional Ownership Trends for Biocept. Which major investors are buying Biocept stock? BIOC stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. View Insider Buying and Selling for Biocept. How do I buy shares of Biocept? Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Biocept's stock price today? One share of BIOC stock can currently be purchased for approximately $1.02. How big of a company is Biocept? Biocept has a market capitalization of $2.32 million and generates $5.07 million in revenue each year. The medical research company earns $-21,610,000.00 in net income (profit) each year or ($23.72) on an earnings per share basis. What is Biocept's official website? The official website for Biocept is http://www.biocept.com. How can I contact Biocept? Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected] MarketBeat Community Rating for Biocept (NASDAQ BIOC)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 229 (Vote Outperform)Underperform Votes: 262 (Vote Underperform)Total Votes: 491MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/25/2019 by MarketBeat.com StaffFeatured Article: What is Depreciation?